Birgit Sawitzki

University Professor

Berlin Institute of Health at Charité - Universitätsmedizin Berlin
Country flagGermany

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (21)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

In a subset of children and adolescents, SARS-CoV-2 infection induces a severe acute hyperinflammatory shock 1 termed multisystem inflammatory syndrome in children (MIS-C) at four to eight weeks after infection. MIS-C is characterized by a specific T cell expansion 2 and systemic hyperinflammation 3 . The pathogenesis of MIS-C remains largely unknown. Here we show that acute MIS-C is characterized by impaired reactivation of virus-reactive memory T cells, which depends on increased serum levels of the cytokine TGFβ resembling those that occur during severe COVID-19 (refs. 4,5 ). This functional impairment in T cell reactivity is accompanied by the presence of TGFβ-response signatures in T cells, B cells and monocytes along with reduced antigen-presentation capabilities of monocytes, and can be reversed by blocking TGFβ. Furthermore, T cell receptor repertoires of patients with MIS-C exhibit expansion of T cells expressing TCRVβ21.3, resembling Epstein–Barr virus (EBV)-reactive T cell clones capable of eliminating EBV-infected B cells. Additionally, serum TGFβ in patients with MIS-C can trigger EBV reactivation, which is reversible with TGFβ blockade. Clinically, the TGFβ-induced defect in T cell reactivity correlates with a higher EBV seroprevalence in patients with MIS-C compared with age-matched controls, along with the occurrence of EBV reactivation. Our findings establish a connection between SARS-CoV-2 infection and COVID-19 sequelae in children, in which impaired T cell cytotoxicity triggered by TGFβ overproduction leads to EBV reactivation and subsequent hyperinflammation.

Year:

2025

Background The majority of patients recovers from severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) coronavirus disease 2019 (COVID-19) without obvious sequelae, but a significant proportion suffers long-term consequences which have been termed post COVID syndrome (PCS). Despite a wide range of considerations on treatment options in PCS and a significant number of trials initiated, only very few results from randomized controlled trials are currently available. In conclusion, there is an evident medical need to identify treatments for patients with PCS. Methods The primary objective of the platform trial RAPID is to assess the impact of different PCS treatments on the overall physical function of patients. Designed as a master protocol, RAPID contains all information that is generic to this adaptive platform trial. Current and future study treatments are specified in intervention-specific appendices (ISA). The first ISA, RAPID_REVIVE is presented in this manuscript. General sections of the master protocol are named as such. RAPID_REVIVE is a double-blind, placebo-controlled, phase II clinical trial evaluating antiviral PCS treatment with vidofludimus calcium (IMU-838). Patients are randomized at a 1:1 ratio to 45 mg/day vidofludimus calcium (22.5 mg for the first 7 days) or placebo during an initialization phase and thereafter using a response-adaptive randomization procedure. The trial includes a screening period of 7 days, a double-blind treatment period of 56 days and a follow-up period of 28 days. The primary outcome is the intra-patient change in physical function measured by the Short Form-36 Physical Function (SF-36-PF) from baseline to day 56. Secondary endpoints include mental and physical health, intensity of fatigue, severity of mental disorder symptoms, and cognitive function. Discussion PCS is a major problem for global health care and the identification of treatment options is urgently needed. Currently, PCS patients are in a situation without evidence-based treatment options, and quality of life, and often mental health are significantly impaired. The purpose of RAPID is to establish an adaptive platform trial protocol which will concert and quicken clinical trials to evaluate the efficacy and safety of different potential treatments for PCS with the aim to expand the very limited evidence base for the treatment of PCS. Trial registration EU Clinical Trials Register (CTIS) ID: 2024–511628-16–00 (RAPID_REVIVE). Registered on 18.03.2024.

Year:

2025

Immune evasion by escape mutations subverts immunity against SARS‐CoV‐2. A role of pan‐coronavirus immunity for more durable protection is being discussed, but has remained understudied. We here investigated the effects of age, mutations, and homo‐/heterologous vaccination regimens on the dominant pan‐coronavirus‐specific cellular and humoral epitope iCope after SARS‐CoV‐2 infection and vaccination in detail. In older individuals, the quantitatively and qualitatively reduced iCope‐reactive CD4 + T cell responses with narrow TCR repertoires could not be enhanced by vaccination and were further compromised by emerging spike mutations. In contrast, pan‐coronavirus‐reactive humoral immunity was affected only by mutations and not by age. Our results reveal a distinct deficiency of the dichotomous layer of pan‐coronavirus immunity in the older, critical for long‐term protection against SARS‐CoV‐2 variants.

Year:

2025

Year:

2025

Myocarditis, characterized by inflammatory cell infiltration, can have multiple etiologies, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or, rarely, mRNA-based coronavirus disease 2019 (COVID-19) vaccination. The underlying cellular and molecular mechanisms remain poorly understood. In this study, we performed single-nucleus RNA sequencing on left ventricular endomyocardial biopsies from patients with myocarditis unrelated to COVID-19 (Non-COVID-19), after SARS-CoV-2 infection (Post-COVID-19) and after COVID-19 vaccination (Post-Vaccination). We identified distinct cytokine expression patterns, with interferon-γ playing a key role in Post-COVID-19, and upregulated IL16 and IL18 expression serving as a hallmark of Post-Vaccination myocarditis. Although myeloid responses were similar across all groups, the Post-Vaccination group showed a higher proportion of CD4 + T cells, and the Post-COVID-19 group exhibited an expansion of cytotoxic CD8 + T and natural killer cells. Endothelial cells showed gene expression changes indicative of vascular barrier dysfunction in the Post-COVID-19 group and ongoing angiogenesis across all groups. These findings highlight shared and distinct mechanisms driving myocarditis in patients with and without a history of SARS-CoV-2 infection or vaccination.

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (45)

Franziska Sotzny

Charité - Universitätsmedizin Berlin

GERMANY
View details

Anja E. Hauser

-

GERMANY
View details

Antigoni Triantafyllopoulou

Prof. Dr.

Charité - Universitätsmedizin Berlin

GERMANY
View details

Florian Kern

Foundation Chair of Immunology

Brighton and Sussex Medical School

UNITED KINGDOM
View details

Sebastian Wisniewski

Charité Universitätsmedizin Berlin - Campus Virchow-Klinikum

GERMANY
View details

Laura Kim

Charité - Universitätsmedizin Berlin

GERMANY
View details

Kristen Radford

The University of Queensland

AUSTRALIA
View details

THI HOANG OANH NGUYEN

University of Melbourne

AUSTRALIA
View details

Wolfram Doehner

Charité - Universitätsmedizin Berlin

GERMANY
View details

Petra Knaus

Freie Universität Berlin

GERMANY
View details

Julia K. Polansky

Prof, Group leader

Charité - Universitätsmedizin Berlin

GERMANY
View details

Carolien van de Sandt

Team Leader/Senior Research Fellow

Murdoch Childrens Research Institute

AUSTRALIA
View details

Michael Mülleder

Head

Charité - Universitätsmedizin Berlin

GERMANY
View details

Rob C.I. Wüst

University of Amsterdam

NETHERLANDS
View details

Mir-Farzin Mashreghi

Group Leader

Deutsches Rheuma-Forschungszentrum Berlin

GERMANY
View details

Christian Meisel

Charité - Universitätsmedizin Berlin

GERMANY
View details

Julian Braun

Charité - Universitätsmedizin Berlin

GERMANY
View details

Christian H. Bucher

Charité - Universitätsmedizin Berlin

GERMANY
View details

Lucie Loyal

Charité - Universitätsmedizin Berlin

GERMANY
View details

Pinkus Tober-Lau

Charité - Universitätsmedizin Berlin

GERMANY
View details

Michael Schmueck-Henneresse

Berlin Institute of Health at Charité - Universitätsmedizin Berlin

GERMANY
View details

Florian Kurth

Bernhard-Nocht-Institut für Tropenmedizin

GERMANY
View details

David Game

Consultant Nephrologist and Honorary Senior Lecturer

-

UNITED KINGDOM
View details

Roman David Bülow

Professor (W1) for Digital Pathology

RWTH Aachen University

GERMANY
View details

Tim Friede

Professor

Universitätsmedizin Göttingen

GERMANY
View details

Leila Amini

Charité - Universitätsmedizin Berlin

GERMANY
View details

Frank Konietschke

Charité - Universitätsmedizin Berlin

GERMANY
View details

Judith Bellmann-Strobl

Charité - Universitätsmedizin Berlin

GERMANY
View details

Sven Geißler

Professor of the Biology of Musculoskeletal Regeneration

Charité - Universitätsmedizin Berlin

GERMANY
View details

Karl Johan Tronstad

Professor in biochemistry and molecular biology

University of Bergen

NORWAY
View details

Marcus Mall

Charité - Universitätsmedizin Berlin

GERMANY
View details

Stefan Frischbutter

Head of Basic Science

Charité Universitätsmedizin Berlin Campus Benjamin Franklin

GERMANY
View details

David Hillus

Charité - Universitätsmedizin Berlin

GERMANY
View details

Simon Haas

Group leader

Deutsches Krebsforschungszentrum

GERMANY
View details

Delphine Kervella

Université de Nantes

FRANCE
View details

Sandy Kroh

Charité - Universitätsmedizin Berlin

GERMANY
View details

Jonathan Seidman

Professor

Harvard University

UNITED STATES
View details

Benedikt Obermayer

Berlin Institute of Health at Charité - Universitätsmedizin Berlin

GERMANY
View details

Anna C Aschenbrenner

Group Leader [W2 equivalent, tenured]

Deutsches Zentrum für Neurodegenerative Erkrankungen

GERMANY
View details

Kathryn Hoffmann

Head of the Department, Univ.-Prof

Medical University of Vienna

AUSTRIA
View details

Jobst F. Roehmel

-

GERMANY
View details

Lisa Ehlers

Charité - Universitätsmedizin Berlin

GERMANY
View details

Frederik Heinrich

Deutsches Rheuma-Forschungszentrum Berlin

GERMANY
View details

Carmen Scheibenbogen

Charité - Universitätsmedizin Berlin

GERMANY
View details

Britt Wildemann

Jena University Hospital

GERMANY
View details